Novartis Achieves Endpoints Phase III Studies on Chronic Obstructive Pulmonary Disease

Sosei Group Corporation ensures the data released by Novartis that this first three QVA149 Phase III research within the treatment of chronic obstructive pulmonary disease (COPD) all suddenly met their own primary endpoints. The SHINE, BRIGHT and ENLIGHTEN research that happen to be part of the IGNITE program exhibit the potential of QVA149 within the treatment of COPD.

The implications SHINE, with a joining of more than 2,100 affected individuals, suddenly met the primary endpoint by demonstrating the superiority in low FEV1 when compared with once-daily indacaterol or once-daily NVA237 in affected individuals by using moderate to severe COPD. Moreover, QVA149 confirmed dominance in drain FEV1 when compared with placebo and open-label tiotropium (18 mcg). The consequences BRIGHT demonstrated that in fact patients encountered substantially better exercise persistence versus placebo.